GlassScriptPhysician profile
Kristen Jackson
NPI 1255727558
$4,255.00
in general payments reported to CMS, 2019-2025
32 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,267 · 2020: $44.87 · 2021: $24.40 · 2022: $140 · 2023: $1,339 · 2024: $1,305 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,779.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,779.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,302.52 | 2019-2024 | Rybelsus, Ozempic |
| Lilly USA, LLC | $487.09 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $461.96 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.65 | 2023-2024 | Jardiance |
| Dexcom, INC. | $190.81 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $156.23 | 2020-2025 | Evenity, Prolia |
| Xeris Pharmaceuticals, INC. | $150.56 | 2023-2024 | Gvoke Hypopen |
| Amneal Pharmaceuticals LLC | $132.21 | 2020-2024 | Unithroid |
| Radius Health, INC. | $123.88 | 2023-2024 | Tymlos |
| Tandem Diabetes Care, INC. | $116.18 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Sanofi-Aventis U.S. LLC | $87.11 | 2023-2024 | |
| Averitas Pharma INC. | $81.06 | 2023-2024 | Qutenza |
| Pfizer INC. | $79.39 | 2023-2024 | |
| Antares Pharma, INC. | $77.75 | 2022-2024 | Xyosted, Tlando, Nocdurna |
| Kyowa Kirin, INC. | $55.64 | 2023-2024 | Crysvita |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $52.23 | 2023-2024 | Afrezza |
| Abbvie INC. | $47.95 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $47.63 | 2023 | Strensiq |
| Halozyme INC | $45.25 | 2023 | |
| Embecta Corp. | $44.11 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Insulet Corporation | $37.19 | 2023-2024 | Omnipod |
| Beta Bionics, INC. | $31.63 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Allergan, INC. | $30.42 | 2019-2022 | |
| Avvisto Therapeutics, LLC | $26.85 | 2024 | Cycloset |
| Sequel Med Tech, LLC | $26.21 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $24.40 | 2021 | |
| Ibsa Pharma INC. | $22.03 | 2024 | Licart, Tirosint |
| Cequr Corporation | $21.96 | 2022 | |
| Alvogen INC | $19.71 | 2023 | Teriparatide |
| Novartis Pharmaceuticals Corporation | $18.19 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.45 | 2023 | Cycloset |
| Ultragenyx Pharmaceutical INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.